Post-polio syndrome


Post-polio syndrome are latent symptoms of poliomyelitis, occurring at about a 25% to 40% rate. It is a viral infection of the nervous system after the initial infection. Symptoms typically occur 15 to 30 years after an initial acute paralytic attack. Symptoms include decreasing muscular function or acute weakness with pain and fatigue. The same symptoms may also occur years after a nonparalytic polio infection.
The precise mechanism that causes PPS is unknown. It shares many features with chronic fatigue syndrome, but, unlike that disorder, it tends to be progressive and can cause loss of muscle strength. Treatment is primarily limited to adequate rest, conservation of available energy, and supportive measures, such as leg braces and energy-saving devices such as powered wheelchairs, analgesia and sleep aids.

Signs and symptoms

After a period of prolonged stability individuals who had been infected and recovered from polio begin to experience new signs and symptoms, characterised by muscular atrophy, weakness, pain and fatigue in limbs that were originally affected or in limbs that didn't seem to have been affected at the time of the initial polio illness. PPS is a very slowly progressing condition marked by periods of stability followed by new declines in the ability to carry out usual daily activities. Most patients become aware of their decreased capacity to carry out daily routines due to significant changes in mobility, decreasing upper limb function and lung capability. Fatigue is often the most disabling symptom; even slight exertion often produces disabling fatigue and can also intensify other symptoms. Problems breathing or swallowing, sleep-related breathing disorders, such as sleep apnea and decreased tolerance for cold temperatures are other notable symptoms.
Increased activity during intervening healthy years between the original infection and onset of PPS can amplify the symptoms. Thus, contracting poliomyelitis at a young age can result in particularly disabling PPS symptoms.
A possible early occurring and long-lasting sign is a slight jitter exhibited in handwriting.

Mechanism

Numerous theories have been proposed to explain post-polio syndrome. Despite this, there are currently no absolutely defined causes of PPS. The most widely accepted theory of the mechanism behind the disorder is "neural fatigue". A motor unit is a nerve cell and the muscle fibers it activates. Poliovirus attacks specific neurons in the brainstem and the anterior horn cells of the spinal cord, generally resulting in the death of a substantial fraction of the motor neurons controlling skeletal muscles. In an effort to compensate for the loss of these neurons, surviving motor neurons sprout new nerve terminals to the orphaned muscle fibers. The result is some recovery of movement and the development of enlarged motor units.
The neural fatigue theory proposes that the enlargement of the motor neuron fibers places added metabolic stress on the nerve cell body to nourish the additional fibers. After years of use, this stress may be more than the neuron can handle, leading to the gradual deterioration of the sprouted fibers and, eventually, the neuron itself. This causes muscle weakness and paralysis. Restoration of nerve function may occur in some fibers a second time, but eventually nerve terminals malfunction and permanent weakness occurs. When these neurons no longer carry on sprouting, fatigue occurs due to the increasing metabolic demand of the nervous system. The normal aging process also may play a role. There is an ongoing denervation and reinnervation, but the reinnervation process has an upper limit where the reinnervation cannot compensate for the ongoing denervation, and loss of motor units takes place. However, what disturbs the denervation-reinnervation equilibrium and causes peripheral denervation is still unclear. With age, most people experience a decrease in the number of spinal motor neurons. Because polio survivors have already lost a considerable number of motor neurons, further age-related loss of neurons may contribute substantially to new muscle weakness. The overuse and underuse of muscles also may contribute to muscle weakness.
Another theory is that people who have recovered from polio lose remaining healthy neurons at a faster rate than normal. However, little evidence exists to support this idea. Finally, it has been proposed that the initial polio infection causes an autoimmune reaction, in which the body's immune system attacks normal cells as if they were foreign substances. Again, compared to neural fatigue, the evidence supporting this theory is quite limited.

Diagnosis

Diagnosis of post-polio syndrome can be difficult, since the symptoms are hard to separate from complications due to the original poliomyelitis infection, and from the normal infirmities of aging. There is no laboratory test for post-polio syndrome, nor are there any other specific diagnostic criteria. Three important criteria are recognized, including: previous diagnosis of polio, long interval after recovery and the gradual onset of weakness.
In general, PPS is a diagnosis of exclusion whereby other possible causes of the symptoms are eliminated. Neurological examination aided by other laboratory studies can help to determine what component of a neuromuscular deficit occurred with polio and what components are new and to exclude all other possible diagnoses. Objective assessment of muscle strength in PPS patients may not be easy. Changes in muscle strength are determined in specific muscle groups using various muscle scales which quantify strength, such as the Medical Research Council scale. Magnetic resonance imaging, neuroimaging, and electrophysiological studies, muscle biopsies, or spinal fluid analysis may also be useful in establishing a PPS diagnosis.

Management

PPS treatment — concerns comfort and rest — is generally of palliative care. There are no reversive therapies. Fatigue is usually the more disabling symptom. Energy conservation can significantly reduce fatigue episodes. Such can be achieved by lifestyle changes: additional sleep, reducing workload, weight loss for obesity. Some require lower limb orthotics to reduce energy usage.
Medications for fatigue, such as amantadine and pyridostigmine, are ineffective in the management of PPS. Muscle strength and endurance training are more important in managing the symptoms of PPS than the ability to perform enduring aerobic activity. Management should focus on treatments such as hydrotherapy and developing other routines that encourage strength but do not affect fatigue levels. A recent trend toward use of intravenous immunoglobulin, which had yielded promising albeit modest results, but proves insufficient to recommend as a treatment.
PPS increasingly stresses the musculoskeletal system from progressive muscular atrophy. A recent study showed that in a review of 539 PPS patients, 80 percent reported pain in muscles and joints and 87 percent had fatigue. Joint instability can cause appreciable pain and should be adequately treated with painkillers. Directed activity — decreasing mechanical stress with braces and adaptive equipment are recommended.
Because PPS can fatigue facial muscles, as well as cause dysphagia, dysarthria or aphonia, persons may become malnourished from difficulty eating. Compensatory routines can help relieve these symptoms such as eating smaller portions at a time and sitting down whilst eating. PPS with respiratory involvement requires exceptional therapy management — breathing exercises, chest percussion toward the expelling of secretions on a periodic basis. Failure to properly assess PPS with respiratory involvement can increase the risk of overlooking an aspiration pneumonia. Severe cases may require permanent ventilation or tracheostomy. Sleep apnoea may also occur. Other management strategies that show improvement include smoking cessation, treatment of other respiratory diseases and vaccination against respiratory infections such as influenza.

Prognosis

In general, PPS is not life-threatening. The major exception are patients left with severe residual respiratory difficulties, who may experience new severe respiratory impairment. Studies have shown that, compared to control populations, PPS patients lack any elevation of antibodies against the poliovirus, and because no poliovirus is excreted in the feces, it is not considered a recurrence of the original polio. Further, there is no evidence that the poliovirus can cause a persistent infection in humans. PPS has been confused with amyotrophic lateral sclerosis, which progressively weakens muscles. PPS patients do not have an elevated risk of ALS.
There have been no sufficient longitudinal studies on the prognosis of post-polio syndrome; however, speculations have been made by several physicians based on experience. Fatigue and mobility usually return to normal over a long period of time. The prognosis also differs depending upon different causes and factors affecting the individual. An overall mortality rate of 25 percent exists due to possible respiratory paralysis of persons with post-polio syndrome; otherwise, post-polio syndrome is usually non-lethal.
Prognosis can be abruptly changed for the worse by the use of anesthesia, such as during surgery.

Epidemiology

Old data shows Post-polio syndrome occurs in approximately 25 to 50 percent of people who survive a poliomyelitis infection. However newer data from countries that have contacted their polio survivors have shown 85% of their polio survivors to have symptoms of Post Polio Syndrome. On average, it occurs 30–35 years afterwards; however, delays of between 8–71 years have been recorded. The disease occurs sooner in persons with more severe initial infection. Other factors that increase the risk of postpolio syndrome include increasing length of time since acute poliovirus infection, presence of permanent residual impairment after recovery from the acute illness, and being female.
Post-polio syndrome is documented to occur in cases of nonparalytic polio. One review states late-onset weakness and fatigue occurs in 14 to 42 percent of NPP patients.